R rating

X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
SG, Private Securities Litigation Reform Act, Research, Therapy, CN, G-CSF, R rating, Obesity, WHIM syndrome, CXCR4, Cancer, Industry, Biology, GLOBE, Degenerative disease, FDA, Population, Safety, Conference, Patient, B-cell lymphoma, NDA, Immunodeficiency, Cyclic neutropenia, CNS, Conference call, Research and development, Central nervous system disease, U.S. Securities and Exchange Commission, Clinical trial, PIPE, Forward-looking statement, ID, Risk, Partnership, Immune system, GSK, R, GlaxoSmithKline, WM, General officer, Security (finance), SEC, ANC, State Administrative Expenses, Pharmaceutical industry, Lithium

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent and upcoming expected milestones.

Key Points: 
  • ET
    BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent and upcoming expected milestones.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $81.1 million in cash, cash equivalents, and restricted cash as of September 30, 2022.
  • R&D expenses include $0.6 million and $0.6 million of certain non-cash expenses for the third quarter of 2022 and 2021, respectively.
  • X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

VAPORESSO Readies XROS 3 for Early December Release

Retrieved on: 
Tuesday, November 1, 2022
SSS, MTL, Limit, R rating, Head, Heat, Muses, Technology, Company, DTL, Quality of life, Red

SHENZHEN, China, Nov. 1, 2022 /PRNewswire/ --VAPORESSO, a world-leading vaping brand, will launch its latest products, the XROS 3 and XROS 3 Mini, on 28th October on its official website, which is predicted to be sold in early December.

Key Points: 
  • SHENZHEN, China, Nov. 1, 2022 /PRNewswire/ --VAPORESSO, a world-leading vaping brand, will launch its latest products, the XROS 3 and XROS 3 Mini, on 28th October on its official website, which is predicted to be sold in early December.
  • The XROS series has built up a worldwide following as one of the most reliable and powerful vape products available on the market.
  • VAPORESSO was created in 2015 and is dedicated to establishing a smoke-free world while raising the quality of life for its users.
  • Based on its continuous innovation, strict quality control, and substantial commitment, VAPORESSO creates products that can fit all levels and styles of vapers.

VAPORESSO Readies XROS 3 for Early December Release

Retrieved on: 
Saturday, October 29, 2022
Company, DTL, Red, Heat, MTL, View, Technology, Multimedia, Quality of life, SSS, Limit, Muses, Head, R rating

SHENZHEN, China, Oct. 28, 2022 /PRNewswire/ --VAPORESSO, a world-leading vaping brand, will launch its latest products, the XROS 3 and XROS 3 Mini, on 28th October on its official website, which is predicted to be sold in early December.

Key Points: 
  • SHENZHEN, China, Oct. 28, 2022 /PRNewswire/ --VAPORESSO, a world-leading vaping brand, will launch its latest products, the XROS 3 and XROS 3 Mini, on 28th October on its official website, which is predicted to be sold in early December.
  • The XROS series has built up a worldwide following as one of the most reliable and powerful vape products available on the market.
  • VAPORESSO was created in 2015 and is dedicated to establishing a smoke-free world while raising the quality of life for its users.
  • Based on its continuous innovation, strict quality control, and substantial commitment, VAPORESSO creates products that can fit all levels and styles of vapers.

VAPORESSO Readies XROS 3 for Early December Release

Retrieved on: 
Saturday, October 29, 2022
Company, DTL, Red, Heat, MTL, Technology, Quality of life, SSS, Limit, Muses, Head, R rating

SHENZHEN, China, Oct. 29, 2022 /PRNewswire/ --VAPORESSO, a world-leading vaping brand, will launch its latest products, the XROS 3 and XROS 3 Mini, on 28th October on its official website, which is predicted to be sold in early December.

Key Points: 
  • SHENZHEN, China, Oct. 29, 2022 /PRNewswire/ --VAPORESSO, a world-leading vaping brand, will launch its latest products, the XROS 3 and XROS 3 Mini, on 28th October on its official website, which is predicted to be sold in early December.
  • The XROS series has built up a worldwide following as one of the most reliable and powerful vape products available on the market.
  • VAPORESSO was created in 2015 and is dedicated to establishing a smoke-free world while raising the quality of life for its users.
  • Based on its continuous innovation, strict quality control, and substantial commitment, VAPORESSO creates products that can fit all levels and styles of vapers.

Western Exploration Amends Articles to Change Name of Listed Shares to "Variable Voting Shares"

Retrieved on: 
Tuesday, October 25, 2022
Mining, Minerals, Natural Resources, News, Time, Review, Achievement, No, Indian stock exchange, Aura, R rating, History, Compliance, Silver, TSX Venture Exchange, Nature, Intention, Gold, Amendment, Proxy, Forward-looking statement, Terminology, FPI, Campaign finance reform amendment, SEDAR, Security (finance), Holding company, Non-U.S. operators of the M60 Patton, Corporation

Western Exploration Inc. (the "Corporation" or "Western Exploration") (TSXV: WEX) (OTCQX: WEXPF) today announces that, in response to regulatory feedback, it has amended its notice of articles to change the identifying name of its outstanding class of shares from "Common Shares" to "Variable Voting Shares" (the "Amendment").

Key Points: 
  • Western Exploration Inc. (the "Corporation" or "Western Exploration") (TSXV: WEX) (OTCQX: WEXPF) today announces that, in response to regulatory feedback, it has amended its notice of articles to change the identifying name of its outstanding class of shares from "Common Shares" to "Variable Voting Shares" (the "Amendment").
  • If the Voting Reduction is triggered, then the Variable Voting Shares held by U.S.
  • Residents (which, for the avoidance of doubt, are the only shares subject to the Voting Reduction) will be treated as a separate series of Variable Voting Shares only for the purposes of voting, and will be called the "Restricted Voting Shares".
  • In other words, a holder of 100 Variable Voting Shares has 31.2 votes after giving effect to the Voting Reduction.

Rights and Issues Investment Trust PLC: Tender Offer

Retrieved on: 
Tuesday, August 30, 2022
Telephone, Tender offer, Annual general meeting, Net asset value, Resolution, Republic, International (Amtrak train), Share (finance), Director, Board, Pancras Square Library, FinnCap, Board of directors, General officer, Mass meeting, R rating, Circular, Tender, Retirement, FTSE, Company, Internet, Common stock, Review, NAV, Financial adviser, Bank, Cryptocurrency, Security (finance), Car rental, Auction, Holding company, CREST, Shareholder, VAT, Euroclear

The Company also announced on 7 June 2022 that the Company would make a tender offer (the Tender Offer) to Shareholders equal to ten per cent.

Key Points: 
  • The Company also announced on 7 June 2022 that the Company would make a tender offer (the Tender Offer) to Shareholders equal to ten per cent.
  • The Tender Offer enables Qualifying Shareholders who wish to realise some or all of their Ordinary Shares to elect to do so (subject to the overall limits applicable to the Tender Offer).
  • of the value at the Tender Price of the Ordinary Shares purchased by finnCap in the Tender Offer).
  • Shareholders are recommended to read the Circular which sets out the full terms and conditions of the Tender Offer and how applications can be made under the Tender Offer.

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Private Securities Litigation Reform Act, ANC, Research and development, Security (finance), COVID-19, WM, MYD88, Clinical trial, CXCR4, Hercules, Wart, R rating, General officer, Patient, Biology, EHA, Immunodeficiency, Safety, U.S. Securities and Exchange Commission, BTK, Conference call, Adult, B-cell lymphoma, Research, European Hematology Association, SG, Forward-looking statement, Cancer, Therapy, Achievement, PIPE, GLOBE, R, Conference, ID, WHIM syndrome, EDT, Medication, State Administrative Expenses, Immune system, Cyclic neutropenia, Risk, Partnership, SEC, Pharmaceutical industry, Lithium, Hypogammaglobulinemia, Infection

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the second quarter ended June 30, 2022. In addition, the company highlighted important upcoming milestones related to its lead clinical candidate, mavorixafor, including the presentation of data from its ongoing Phase 1b clinical trial in chronic neutropenic disorders and from the global, pivotal Phase 3 clinical trial of mavorixafor in WHIM (Warts, Hypogammaglobulinemia, Infections, & Myelokathexis) syndrome. The company also provided an update on its clinical oncology program following its recent strategic announcement prioritizing its use of resources to advance mavorixafor solely in chronic neutropenic disorders.

Key Points: 
  • R&D expenses include $0.7 million and $0.8 million of certain non-cash expenses for the second quarter of 2022 and 2021, respectively.
  • SG&A expenses include $0.8 million and $1.0 million of certain non-cash expenses for the second quarter of 2022 and 2021, respectively.
  • Net losses include $1.5 million and $1.8 million of certain non-cash expenses for the second quarter of 2022 and 2021, respectively.
  • X4 will host a conference call and webcast today at 8:30 am EDT to discuss financial results and business highlights.

Officially Launched! “1st Disposable Pod Mod” ZOVOO DRAGBAR R6000 Unveils the Mystery

Retrieved on: 
Friday, July 1, 2022
Tobacco, Retail, Specialty, Other Retail, Efficiency, RDL, TikTok, R rating, Nicotine, Industry, Technology, R6000, Facebook, Instagram, Taste, Multimedia, Ceramic, Online shopping, Mesh

The outstanding performance of ZOVOO has conquered everyone again, attracting the attention of numerous media, partners and global fans!

Key Points: 
  • The outstanding performance of ZOVOO has conquered everyone again, attracting the attention of numerous media, partners and global fans!
  • 1st Disposable Pod Mod ZOVOO DRAGBAR R6000 unveils the mystery (Photo: Business Wire)
    Let's take a look at the new products and highlights of the event:
    As the first disposable product in the DRAG family, the new DRAGBAR R6000 combines the professional vaping experience with the convenience of disposable products.
  • DRAGBAR R6000 has maximum output power 18W and upgraded 18ml super large e-liquid capacity.
  • ZOVOO offers the lightest and thinnest ceramic core disposable product-- DRAGBAR Z700 GT, which adopts the latest upgraded ceramic core technology, and reconstructs a new thin and light experience.

X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
SCN, Risk, ID, Achievement, Disease, Population, R, Neoplasm, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, R rating, EDT, Patient, Genetic testing, Biology, CXCR4, CIS, Degenerative disease, Clinical trial, WHIM syndrome, COVID-19, MYD88, PID, Neutropenia, Research, Pids, Research and development, General officer, Awareness, Conference, Conference call, Medication, Forward-looking statement, SG, Safety, Immunodeficiency, Therapy, Immune system, SEC, Cancer, Prevalence, Diagnosis, Security (finance), Publishing, State Administrative Expenses, GLOBE, Pharmaceutical industry, Lithium

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, (Nasdaq: XFOR), a leader in the discovery and development of novel oral CXCR4-targeted small molecule therapeutics to benefit people with rare immune system disorders, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Cash, Cash Equivalents & Restricted Cash: X4 had $67.7 million in cash, cash equivalents, and restricted cash as of March 31, 2022.
  • The company expects that its cash and cash equivalents will fund company operations into the fourth quarter of 2022.
  • R&D expenses include $0.7 million and $0.6 million of certain non-cash expenses for the first quarter of 2022 and 2021, respectively.
  • X4 will host a conference call and webcast today at 8:30 am EDT to discuss financial results and business highlights.

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 17, 2022
Mutation, PID, State Administrative Expenses, Conference, Risk, Pids, Immunoglobulin M, G&A, EDT, Lymphocyte, U.S. Securities and Exchange Commission, Severe congenital neutropenia, WHIM syndrome, SEC, R rating, Private Securities Litigation Reform Act, AACR, COVID-19, Medication, Wart, Forward-looking statement, Completeness, Clinical trial, Neutrophil, Research, Cancer, Immune system, Research and development, Genetic testing, Society, Oral, CIS, Conference call, Monocyte, Therapy, ASH, Security (finance), Prevalence, Clear cell renal cell carcinoma, Achievement, Disease, GLOBE, ID, Immunodeficiency, SCN, Safety, Adult, Axitinib, R, Biology, Pharmaceutical industry, Vaccine, Lithium, Infection, Hypogammaglobulinemia, CXCR4, Patient

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the fourth quarter and twelve months ended December 31, 2021, and provided a corporate update.

Key Points: 
  • Top-line data from the 4WHIM trial are expected in the fourth quarter of 2022.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $83.1 million in cash, cash equivalents, and restricted cash as of December 31, 2021.
  • The company expects that its cash and cash equivalents will fund company operations into the fourth quarter of 2022.
  • X4 will host a conference call and webcast today at 8:30 am EDT to discuss financial results and business highlights.